Natco Pharma’s arm launches NAT-LENALIDOMIDE Capsules
2nd Sep 2021

Natco Pharma’s subsidiary -- Natco Pharma (Canada) Inc. has launched NAT-LENALIDOMIDE Capsules, the first generic alternative to Revlimid to be approved by Health Canada.

NAT-LENADLIDOMIDE is used in combination with dexamethasone for the treatment of multiple myeloma in patients who are not eligible for stem cell transplant. NAT-LENALIDOMIDE is also indicated for treatment of transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion of 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.